Calidi Biotherapeutics, Inc.
CLDWW- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCLDI
Q1 2022 vs. Q4 2021
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 23 | 29 | +6 |
| Shares | 5.80M | 7.51M | +1.71M (+29.5%) |
| Value | $3.01M | $2.83M | −$175.0K (−5.8%) |
New holders (8)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nomura Holdings Inc | 467,818 | $196.0K | 0.00% |
| Shaolin Capital Management LLC | 497,838 | $179.0K | 0.00% |
| Aristeia Capital LLC | 495,000 | $165.0K | 0.00% |
| Ionic Capital Management LLC | 234,913 | $85.0K | 0.01% |
| JPMorgan Chase & Co | – | $53.0K | 0.00% |
| EHP Funds Inc. | 134,320 | $48.0K | 0.01% |
| Cowen and Company, LLC | 99,600 | $36.0K | 0.00% |
| Susquehanna International Group, LLP | 11,742 | $4.00K | 0.00% |
Sold out (2)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Beryl Capital Management LLC | 629,999 | $315.0K |
| Q Global Advisors, LLC | 100,000 | $50.0K |